Is QDEL or EMBC more profitable?

Embecta has a net margin of 8.59% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets QuidelOrtho -39.20% 4.88% 1.63% Embecta 8.59% -19.25% 10.82%

Does the media favor QDEL or EMBC?

In the previous week, QuidelOrtho and QuidelOrtho both had 5 articles in the media. QuidelOrtho's average media sentiment score of 0.73 beat Embecta's score of 0.34 indicating that QuidelOrtho is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment QuidelOrtho 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, CERS or EMBC?

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $206.13M 2.55 -$15.63M -$0.03 N/A Embecta $1.08B 0.29 $95.40M $1.48 3.80

Is CERS or EMBC more profitable?

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Cerus -3.06% -10.19% -3.14% Embecta 8.59% -19.25% 10.82%

Does the media favor CERS or EMBC?

In the previous week, Embecta had 2 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Embecta and 3 mentions for Cerus. Cerus' average media sentiment score of 0.56 beat Embecta's score of 0.34 indicating that Cerus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cerus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, SMTI or EMBC?

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 3.13 -$37.56M -$3.59 N/A Embecta $1.08B 0.29 $95.40M $1.48 3.80

Is SMTI or EMBC more profitable?

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Sanara MedTech -29.15% 29.72% 2.84% Embecta 8.59% -19.25% 10.82%

Does the media favor SMTI or EMBC?

In the previous week, Embecta had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Embecta and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.91 beat Embecta's score of 0.34 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, EMBC or RXST?

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.08B 0.29 $95.40M $1.48 3.80 RxSight $134.48M 1.46 -$38.94M -$1.13 N/A

Is EMBC or RXST more profitable?

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 8.59% -19.25% 10.82% RxSight -36.80% -17.35% -14.70%

Does the media refer more to EMBC or RXST?

In the previous week, RxSight had 3 more articles in the media than Embecta. MarketBeat recorded 8 mentions for RxSight and 5 mentions for Embecta. Embecta's average media sentiment score of 0.34 beat RxSight's score of -0.05 indicating that Embecta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral RxSight 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Embecta (EMBC) Competitors

$5.62 +0.04 (+0.72%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$5.62 +0.00 (+0.09%)

As of 09/24/2026 07:30 PM Eastern

Compare

EMBC vs. QDEL, CERS, SMTI, RXST, and OSUR

Should you buy Embecta stock or one of its competitors? Embecta's main competitors and comparable companies include QuidelOrtho (QDEL), Cerus (CERS), Sanara MedTech (SMTI), RxSight (RXST), and OraSure Technologies (OSUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Embecta compare to QuidelOrtho?

QuidelOrtho (NASDAQ:QDEL) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Embecta has lower revenue, but higher earnings than QuidelOrtho. QuidelOrtho is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
QuidelOrtho	$2.73B	0.27	-$1.13B	-$15.41	N/A
Embecta	$1.08B	0.29	$95.40M	$1.48	3.80

99.0% of QuidelOrtho shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 1.1% of QuidelOrtho shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Embecta has a net margin of 8.59% compared to QuidelOrtho's net margin of -39.20%. QuidelOrtho's return on equity of 4.88% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
QuidelOrtho	-39.20%	4.88%	1.63%
Embecta	8.59%	-19.25%	10.82%

QuidelOrtho presently has a consensus target price of $13.63, indicating a potential upside of 27.46%. Embecta has a consensus target price of $11.00, indicating a potential upside of 95.73%. Given Embecta's stronger consensus rating and higher probable upside, analysts plainly believe Embecta is more favorable than QuidelOrtho.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
QuidelOrtho	3 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

QuidelOrtho has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Embecta has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

In the previous week, QuidelOrtho and QuidelOrtho both had 5 articles in the media. QuidelOrtho's average media sentiment score of 0.73 beat Embecta's score of 0.34 indicating that QuidelOrtho is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
QuidelOrtho	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Embecta beats QuidelOrtho on 10 of the 14 factors compared between the two stocks.

How does Embecta compare to Cerus?

Cerus (NASDAQ:CERS) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Embecta has a net margin of 8.59% compared to Cerus' net margin of -3.06%. Cerus' return on equity of -10.19% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cerus	-3.06%	-10.19%	-3.14%
Embecta	8.59%	-19.25%	10.82%

Cerus presently has a consensus price target of $5.25, suggesting a potential upside of 101.15%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 95.73%. Given Cerus' stronger consensus rating and higher possible upside, research analysts clearly believe Cerus is more favorable than Embecta.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cerus	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

In the previous week, Embecta had 2 more articles in the media than Cerus. MarketBeat recorded 5 mentions for Embecta and 3 mentions for Cerus. Cerus' average media sentiment score of 0.56 beat Embecta's score of 0.34 indicating that Cerus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cerus	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.4% of Cerus shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 5.3% of Cerus shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cerus has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Embecta has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Embecta has higher revenue and earnings than Cerus. Cerus is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cerus	$206.13M	2.55	-$15.63M	-$0.03	N/A
Embecta	$1.08B	0.29	$95.40M	$1.48	3.80

Summary

Cerus and Embecta tied by winning 8 of the 16 factors compared between the two stocks.

How does Embecta compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Embecta (NASDAQ:EMBC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

Embecta has a net margin of 8.59% compared to Sanara MedTech's net margin of -29.15%. Sanara MedTech's return on equity of 29.72% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-29.15%	29.72%	2.84%
Embecta	8.59%	-19.25%	10.82%

In the previous week, Embecta had 3 more articles in the media than Sanara MedTech. MarketBeat recorded 5 mentions for Embecta and 2 mentions for Sanara MedTech. Sanara MedTech's average media sentiment score of 0.91 beat Embecta's score of 0.34 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Embecta has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	3.13	-$37.56M	-$3.59	N/A
Embecta	$1.08B	0.29	$95.40M	$1.48	3.80

Sanara MedTech currently has a consensus price target of $35.00, suggesting a potential downside of 0.28%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 95.73%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than Sanara MedTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60

Sanara MedTech has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Embecta has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Embecta beats Sanara MedTech on 9 of the 15 factors compared between the two stocks.

How does Embecta compare to RxSight?

Embecta (NASDAQ:EMBC) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

In the previous week, RxSight had 3 more articles in the media than Embecta. MarketBeat recorded 8 mentions for RxSight and 5 mentions for Embecta. Embecta's average media sentiment score of 0.34 beat RxSight's score of -0.05 indicating that Embecta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
RxSight	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.8% of Embecta shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Embecta has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, RxSight has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 95.73%. RxSight has a consensus price target of $8.17, suggesting a potential upside of 72.77%. Given Embecta's higher probable upside, equities research analysts plainly believe Embecta is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

Embecta has higher revenue and earnings than RxSight. RxSight is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.29	$95.40M	$1.48	3.80
RxSight	$134.48M	1.46	-$38.94M	-$1.13	N/A

Embecta has a net margin of 8.59% compared to RxSight's net margin of -36.80%. RxSight's return on equity of -17.35% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
RxSight	-36.80%	-17.35%	-14.70%

Summary

Embecta beats RxSight on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to OraSure Technologies?

Embecta (NASDAQ:EMBC) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Embecta has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Embecta has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.08B	0.29	$95.40M	$1.48	3.80
OraSure Technologies	$115.02M	2.36	-$68.73M	-$0.69	N/A

In the previous week, Embecta had 4 more articles in the media than OraSure Technologies. MarketBeat recorded 5 mentions for Embecta and 1 mentions for OraSure Technologies. OraSure Technologies' average media sentiment score of 1.25 beat Embecta's score of 0.34 indicating that OraSure Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Embecta	Neutral
OraSure Technologies	Positive

Embecta has a net margin of 8.59% compared to OraSure Technologies' net margin of -43.70%. OraSure Technologies' return on equity of -19.09% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	8.59%	-19.25%	10.82%
OraSure Technologies	-43.70%	-19.09%	-16.26%

93.8% of Embecta shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Embecta currently has a consensus price target of $11.00, suggesting a potential upside of 95.73%. OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 23.66%. Given Embecta's stronger consensus rating and higher possible upside, research analysts clearly believe Embecta is more favorable than OraSure Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	2 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
OraSure Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Embecta beats OraSure Technologies on 10 of the 15 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$316.73M	$5.63B	$7.32B	$13.29B
Dividend Yield	0.72%	1.79%	2.52%	12.57%
P/E Ratio	3.80	25.36	274.40	25.76
Price / Sales	0.29	71.00	688.47	106.32
Price / Cash	1.40	33.02	77.80	52.76
Price / Book	-0.51	5.74	10.52	6.34
Net Income	$95.40M	$151.55M	$3.49B	$360.00M
7 Day Performance	6.54%	-0.45%	-0.94%	-0.16%
1 Month Performance	11.73%	-4.20%	-4.24%	-4.07%
1 Year Performance	-58.95%	7.41%	16.39%	5.97%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EMBC Embecta	3.9254 of 5 stars	$5.62 +0.7%	$11.00 +95.7%	-61.5%	$316.73M	$1.08B	3.80	1,850
QDEL QuidelOrtho	3.4371 of 5 stars	$11.09 -0.3%	$13.63 +22.9%	-59.9%	$759.13M	$2.67B	N/A	6,500	News Coverage
CERS Cerus	1.7689 of 5 stars	$2.52 -1.4%	$5.25 +108.7%	+69.5%	$506.84M	$221.55M	N/A	345	News Coverage Positive News
SMTI Sanara MedTech	0.6146 of 5 stars	$35.13 +0.4%	$35.00 -0.4%	+7.8%	$322.82M	$103.12M	N/A	108	News Coverage
RXST RxSight	2.4284 of 5 stars	$5.70 -6.8%	$8.37 +46.9%	-48.5%	$236.33M	$127.58M	N/A	461	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors